Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: report from the SENTRY antimicrobial surveillance programme (2007-09).
about
Laboratory Detection and Clinical Implication of Oxacillinase-48 like Carbapenemase: The Hidden ThreatDissemination of carbapenemases producing Gram negative bacteria in the Middle EastMolecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11An update on the management of urinary tract infections in the era of antimicrobial resistance.Carbapenem-resistant enterobacteriaceae: an emerging problem in children.Bacterial Epidemiology and Antimicrobial Resistance in the Surgery Wards of a Large Teaching Hospital in Southern Italy.Extraintestinal Pathogenic Escherichia coli: A Combination of Virulence with Antibiotic ResistanceSurveillance and molecular epidemiology of Klebsiella pneumoniae isolates that produce carbapenemases: first report of OXA-48-like enzymes in North America.β-Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates.Gram-negative bacteria that produce carbapenemases causing death attributed to recent foreign hospitalization.Screening for Gram-negative bacteria: Impact of preanalytical parameters.Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae.In Vitro Evaluation of the Activity of Imipenem-Relebactam against 451 Recent Clinical Isolates of Bacteroides Group and Related Species.Antibiotic resistance & pathogen profile in ventilator-associated pneumonia in a tertiary care hospital in IndiaThe role of international travel in the worldwide spread of multiresistant Enterobacteriaceae.Extraintestinal pathogenic Escherichia coli: an update on antimicrobial resistance, laboratory diagnosis and treatment.Current strategies for the treatment of complicated intraabdominal infections.Recent developments in antibiotic agents for the treatment of complicated intra-abdominal infections.Antimicrobial activity of ceftaroline-avibactam tested against clinical isolates collected from U.S. Medical Centers in 2010-2011.Molecular β-Lactamase Characterization of Aerobic Gram-Negative Pathogens Recovered from Patients Enrolled in the Ceftazidime-Avibactam Phase 3 Trials for Complicated Intra-abdominal Infections, with Efficacies Analyzed against Susceptible and ResisLow Frequency of Ceftazidime-Avibactam Resistance among Enterobacteriaceae Isolates Carrying blaKPC Collected in U.S. Hospitals from 2012 to 2015.Prevalence and Antibiotic Susceptibility Patterns of Extended-Spectrum ß-Lactamase and Metallo-ß-Lactamase-Producing Uropathogenic Escherichia coli Isolates.Rapid Flow Cytometry Test for Identification of Different Carbapenemases in EnterobacteriaceaeContemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groupsActivity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types.Regional resistance surveillance program results for 12 Asia-Pacific nations (2011).Potency and spectrum of activity of AN3365, a novel boron-containing protein synthesis inhibitor, tested against clinical isolates of Enterobacteriaceae and nonfermentative Gram-negative bacilli.In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria.Diversity of extended-spectrum and plasmid-mediated AmpC β-lactamases in Enterobacteriaceae isolates from Portuguese health care facilities.Expansion of clonal complex 258 KPC-2-producing Klebsiella pneumoniae in Latin American hospitals: report of the SENTRY Antimicrobial Surveillance ProgramCarbapenem-resistant Gram-negative bacilli in Canada 2009-10: results from the Canadian Nosocomial Infection Surveillance Program (CNISP).Activity of ceftaroline and comparator agents tested against contemporary Gram-positive and -negative (2011) isolates collected in Europe, Turkey, and Israel.Beginning and possibly the end of the antibiotic era.Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae.Trends in Resistance to Carbapenems and Third-Generation Cephalosporins among Clinical Isolates of Klebsiella pneumoniae in the United States, 1999–2010Analyses of a Ceftazidime-Avibactam-Resistant Isolate Carrying Reveals a Heterogenous Population and Reversible Genotype
P2860
Q26751295-62F099D1-1C6B-4B32-98CC-C960D6796A43Q26771490-D692E7E6-2183-4886-90A0-197B6677FB5AQ28288964-AD3A57D6-9B92-4A6F-9372-58F86FD4CF7CQ30244815-AAFF8753-81AC-4056-86EB-7E791E66F301Q34281727-BBA3D40B-3055-4FE3-B9C8-43CF1ACC8F42Q35669939-4B8237AA-B974-46D5-BB3E-A3561CF3B82BQ35681590-75A1DEED-060E-4DD6-81FC-FE58C03C156FQ36505545-0459F81F-11E3-4B96-9367-26F69C3E0A31Q36644786-72C24B83-6F5B-4E2A-9D1A-9D526805D785Q36969763-F3953E40-F1FA-4D84-B8F2-26FEF3BC2A65Q37128301-EF681CAA-CB30-4757-AB0E-CBB77E2A4972Q37203731-B560E625-49F9-46EE-A984-E8BC15B74EA7Q37287819-8837143B-E9B5-4B03-BBD1-EAFC07D5F74CQ37658663-76C2514B-AA9B-44C9-809D-753B017B5E1BQ38017141-77E8973C-6CE7-4DB4-B5E5-FE367E9A8A4FQ38063968-5C5B43A8-3B89-432B-BB81-F2E81F20E1B6Q38123247-6E15C183-4B07-40FC-95F7-9A91DFDD758CQ38648594-515B2F53-6BB9-440E-8FE2-3FB8936CC24DQ39766920-42A1A119-DA72-4ABB-87FF-146944FBC6F0Q40276518-F994E140-A86C-47AA-BB90-7139DBFBFB64Q40392503-FA922021-C791-4EF9-9914-68A5682982D6Q41700834-5E9C1F3D-4910-4376-9E59-5EC252DEA64AQ41906266-94AB9820-47C4-4AB0-A75B-9B166EDDBE74Q41907738-E89F952A-9B0B-4233-A5D9-1C907CC6F2CEQ41919138-FBFE7CAF-21B7-4276-B7DB-8CDEE7981060Q41956234-EF0103C0-7A2A-425A-BCAC-CAA53B207AEEQ41974370-C156CFBB-4B9B-45E2-ACD9-8E52FA1C508DQ42186280-BFE73052-8DC8-4F4F-9008-67BE0A8780E4Q42213355-661ED5A1-673D-4E4D-AFC3-55D6FB470C54Q42598763-F762BF15-92CD-43EA-8124-5A850E89ED35Q44458638-68D2FDB4-48FC-4041-BC67-9C196625099EQ44796743-0CAA8E9B-0AB1-44CA-BD0C-6BF128F7BCE4Q48333800-ECE2C9E9-433C-4650-81D7-A2733C5173B9Q53735018-586EC707-032F-4F9F-A1E8-274B8D207C66Q56909843-20404459-8C91-4E4A-9CD4-6F4C4AF44E91Q58695311-CDBC1249-8777-4637-BFEE-AE50F4F4E688
P2860
Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: report from the SENTRY antimicrobial surveillance programme (2007-09).
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Trends in carbapenemase-produc ...... veillance programme (2007-09).
@en
Trends in carbapenemase-produc ...... crobial surveillance programme
@nl
type
label
Trends in carbapenemase-produc ...... veillance programme (2007-09).
@en
Trends in carbapenemase-produc ...... crobial surveillance programme
@nl
prefLabel
Trends in carbapenemase-produc ...... veillance programme (2007-09).
@en
Trends in carbapenemase-produc ...... crobial surveillance programme
@nl
P2093
P356
P1476
Trends in carbapenemase-produc ...... veillance programme (2007-09).
@en
P2093
Leah N Woosley
Rodrigo E Mendes
Ronald N Jones
P304
P356
10.1093/JAC/DKR081
P407
P577
2011-03-18T00:00:00Z